Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 693 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Dermatitis Clear all
Completed Phase 2 Interventional

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

NCT01568489
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
HL-009 Liposomal Gel, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Arlington Heights, Illinois • Fridley, Minnesota • Berlin, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

NCT03654755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
160
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 21, 2026, 1:32 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

NCT05952986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB825 or Placebo in subcutaneous route, FB825 in intravenous route
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Results available

Evaluating Treatment Resistant Dermatitis TaroIIR

NCT03050294
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Phone calls, Desoximetasone 0.25% spray
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

NCT02950922
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment
Drug · Other
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
12 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 21, 2026, 1:32 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Systems Biology of Early Atopy

NCT04798079
View directory record Official record
Conditions
Allergic Diseases, Food Allergy, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2032
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Withdrawn Not applicable Interventional

Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children

NCT03843437
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tencel Therapeutic Garments, Cotton Therapeutic Garments
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Months to 6 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

NCT03107611
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Placebo Cream
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
8 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 21, 2026, 1:32 AM EDT
Completed No phase listed Observational

Oral Bacteria and Allergic Disease in Children

NCT00438646
View directory record Official record
Conditions
Asthma, Rhinitis, Eczema, Respiratory Sounds, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

NCT03058783
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IDP-124 Lotion, IDP-124 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 21, 2026, 1:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bathing Babies and Allergy

NCT03050658
View directory record Official record
Conditions
Atopic Dermatitis, Allergy
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
0 Hours to 72 Hours
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 21, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

NCT07783425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Huntington Beach, California • Northridge, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

NCT02791308
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 90 Years
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TS022, Vehicle
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
La Jolla, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

NCT03559270
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
53
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 21, 2026, 1:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

NCT07453602
View directory record Official record
Conditions
Atopic Dermatitis (AD), Eczema
Interventions
ARQ-234, Placebo
Biological · Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Plainfield, Indiana • Fair Lawn, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Flourish: Exploring the Early Infant Gut Microbiome

NCT07333482
View directory record Official record
Conditions
Microbiota, Gut Microbiome, Eczema, Microbiome
Interventions
Tailored Recommendations, Consult Call, Educational Email Series
Dietary Supplement · Behavioral
Lead sponsor
Seeding Inc
Industry
Eligibility
0 Months to 3 Months
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 76 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Suspended Phase 3 Interventional

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

NCT07265479
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%, Vehicle Cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
3 Months to 23 Months
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Bryant, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Not applicable Interventional Results available

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

NCT02289989
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oregano extract cream, Hydrocortisone
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 1:32 AM EDT